Sleep Disorder Market Report 2026

The sleep disorder market size has grown rapidly in recent years. It will grow from $33.32 billion in 2025 to $38.23 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing awareness about sleep health, rising prevalence of insomnia and sleep apnea, growing adoption of sleep diagnostic services, increasing geriatric population, rising stress and lifestyle-related sleep issues, growing smartphone and wearable device usage for sleep tracking.

The sleep disorder market size is expected to see rapid growth in the next few years. It will grow to $65.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of telemedicine services for sleep disorders, rising adoption of wearable sleep trackers, increasing home-based diagnostic testing, growth of cognitive behavioral therapy applications, rising government initiatives on sleep health awareness. Major trends in the forecast period include advancement in wearable sleep monitoring devices, advancement in home-based sleep diagnostic tools, advancement in AI-driven sleep analysis, innovation in non-invasive therapies for sleep apnea, innovation in telemedicine for sleep consultation, innovation in cognitive behavioral therapy apps.

The rising levels of stress and anxiety are expected to propel the growth of the sleep disorder market going forward. Stress and anxiety levels refer to the widespread experience of psychological strain and persistent worry within a population, often arising from environmental, social, or economic pressures. These levels are increasing largely due to work-related challenges, as individuals face heavier workloads, strict deadlines, and growing job insecurity. Elevated stress and anxiety contribute to sleep disorders by disrupting normal sleep patterns and making it harder to fall asleep or maintain uninterrupted sleep. They also negatively affect overall health by reducing restorative sleep, leading to fatigue, diminished cognitive function, and a higher risk of chronic health conditions. For instance, in May 2024, according to the American Psychiatric Association (APA), a US-based professional association, 43% of U.S. adults reported feeling more anxious in 2024 than in the previous year, up from 37% in 2023 and 32% in 2022. Therefore, increasing stress and anxiety levels are driving the growth of the sleep disorder market.

Major companies operating in the sleep disorder market are focusing on developing advanced therapeutic technologies, such as electrical vestibular nerve stimulation (VeNS) methods, to provide non-drug treatment options that improve sleep quality, regulate circadian rhythms, and support patients with chronic insomnia. Electrical vestibular nerve stimulation (VeNS) refers to a non-invasive therapeutic approach that delivers low-level electrical pulses to the vestibular nerve, a key neural pathway that influences brain regions involved in sleep regulation, without the need for surgical intervention or pharmaceuticals. For instance, in October 2024, Neurovalens Ltd., a UK-based health-tech company, launched Modius Sleep, an FDA-cleared, non-invasive device designed to treat chronic insomnia using VeNS technology. The headset-style medical device is worn for approximately 30 minutes each evening and delivers safe electrical pulses to the vestibular nerve, targeting the hypothalamus and brainstem regions responsible for circadian rhythm and sleep regulation, thereby helping users fall asleep faster and maintain longer, more consistent sleep.

In July 2023, ResMed Inc., a US-based provider of sleep and respiratory care solutions, acquired Somnoware Healthcare Systems Inc. for an undisclosed amount. Through this acquisition, ResMed expanded its digital health and diagnostic capabilities by integrating Somnoware’s software to strengthen sleep disorder diagnosis, workflow efficiency, and patient management across clinics and sleep laboratories. Somnoware Healthcare Systems Inc. is a US-based healthcare software company that specializes in solutions for sleep disorder diagnosis and care management.

Major companies operating in the sleep disorder market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Biogen Inc., Union Chimique Belge S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Neurocrine Biosciences Inc., Harmony Biosciences Holdings Inc., Vanda Pharmaceuticals Inc.

North America was the largest region in the sleep disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sleep disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sleep disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have moderately impacted the sleep disorder market by increasing costs for imported diagnostic devices, monitoring equipment, and medical electronics used in sleep testing and treatment. hospital sleep centers and home sleep testing segments are most affected, particularly in regions such as north america, europe, and asia-pacific where cross-border sourcing is common. higher costs have slowed procurement cycles for advanced sleep diagnostics. however, tariffs have encouraged regional manufacturing, local supplier development, and innovation in cost-effective sleep monitoring solutions, supporting long-term market stability.

Sleep disorders refer to a range of conditions that interfere with the body’s normal sleep patterns, affecting the ability to fall asleep, remain asleep, or obtain restful sleep. These disorders may arise from physiological, neurological, or behavioral factors that disrupt healthy sleep cycles. They commonly result in reduced daytime functioning, impaired concentration, and adverse effects on overall well-being.

The primary disorder types of sleep disorder management include insomnia, sleep apnea, restless legs syndrome, narcolepsy, and circadian rhythm disorders. Insomnia refers to difficulty falling asleep, staying asleep, or achieving restorative sleep, often requiring targeted interventions to improve sleep quality and overall health. Treatment options include cognitive behavioral therapy, medication therapy, psychiatric treatment, and behavioral treatment. Diagnostic methods include polysomnography, home sleep testing, actigraphy, sleep diaries, and questionnaires or screening. Distribution occurs through retail pharmacies, online sales, and hospital pharmacies, and the key end users include hospitals and sleep centers, home care settings, and academic and research institutes.

The sleep disorder market consists of revenues earned by entities through sleep clinics, diagnostic sleep studies (polysomnography), cognitive and behavioral sleep therapy, sleep consultation, and monitoring services for sleep-related conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.